REGENXBIO Gestion
Gestion contrôle des critères 3/4
Le PDG REGENXBIO est Curran Simpson, nommé en Jul2024, a un mandat de 1.83 ans. La rémunération annuelle totale est $ 4.20M, composée du salaire de 15.8% et des bonus 84.2%, y compris les actions et options de la société. détient directement 0.089% des actions de la société, d'une valeur de $ 273.48K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.1 ans et 8.9 ans.
Informations clés
Curran Simpson
Directeur général
US$4.2m
Rémunération totale
| Pourcentage du salaire du PDG | 15.84% |
| Durée du mandat du directeur général | 1.8yrs |
| Propriété du PDG | 0.09% |
| Durée moyenne d'occupation des postes de direction | 7.1yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 8.9yrs |
Mises à jour récentes de la gestion
Recent updates
Seeking Alpha • May 16
Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results
Summary REGENXBIO is downgraded from "Buy" to "Hold" due to regulatory setbacks and uncertain approval pathways. The company received a Complete Response Letter for RGX-121 (MPS II), faces an uncertain appeals process, and regulatory demands for more rigorous data. Positive phase 3 data for RGX-202 for DMD patients showed strong biomarker and functional results, but FDA Accelerated Approval on Surrogate endpoint remains uncertain for now. Upcoming catalysts include pivotal wet-AMD trial data in Q4 2026, but the cash runway only extends into early 2027, raising financing concerns. Read the full article on Seeking Alpha
Mise à jour du récit • Apr 26
RGNX: Future Gene Therapy Milestones Will Test Regulatory Risk And Support Bullish Reassessment
REGENXBIO's consensus analyst price target has been revised lower, with cuts ranging from about $1 to $12 as analysts factor in updated clinical timelines, recent FDA commentary around RGX-121 and the approach to rare disease, as well as upcoming pivotal readouts for key gene therapy programs. Analyst Commentary Recent research updates show that while several firms still carry positive ratings on REGENXBIO, they have been trimming price targets and highlighting a more cautious setup around regulatory risk, clinical execution, and timelines for key programs.Mise à jour du récit • Apr 11
RGNX: Future Pivotal Gene Therapy Readouts Will Drive Bullish Reassessment
Analysts have nudged their average price target for REGENXBIO slightly lower to reflect recent target cuts across firms, while still highlighting upcoming regulatory updates and pivotal readouts in Duchenne muscular dystrophy and wet age related macular degeneration as key drivers for their updated views. Analyst Commentary Recent research updates show that while upcoming data and regulatory milestones remain central to the REGENXBIO story, several price targets have been adjusted lower following the latest quarterly results and clinical updates.Mise à jour du récit • Mar 28
RGNX: Future Gene Therapy Milestones Will Drive Reassessment Despite Regulatory Uncertainty
Analysts have nudged their blended price target for REGENXBIO modestly lower by a few dollars to reflect recent reductions in firm level targets, while still pointing to upcoming regulatory updates and pivotal readouts across programs like RGX-202 and ABBV-RGX-314 as key factors in their outlook. Analyst Commentary Street research around REGENXBIO has tilted more cautious in recent weeks, with several price targets adjusted lower following the latest quarterly update, recent regulatory news and evolving views on the company’s gene therapy portfolio.Mise à jour du récit • Mar 12
RGNX: Future Gene Therapy Readouts Will Drive Reassessment Despite Regulatory Setbacks
Analysts have trimmed their average price targets on REGENXBIO, with cuts such as $32 to $30, $45 to $42 and $18 to $17. These changes reflect updated assumptions for slightly lower revenue growth and profit margins, partly offset by a modestly lower discount rate and a higher future P/E multiple.Mise à jour du récit • Feb 26
RGNX: Regulatory Resolution And Gene Therapy Data Will Drive Reassessment
Analysts have trimmed their price targets on REGENXBIO by up to $12, reflecting updated views on RGX-121 related regulatory uncertainty and revised assumptions for the discount rate, revenue growth, profit margin and future P/E, while the central fair value estimate remains at $12.00. Analyst Commentary Recent research updates around REGENXBIO have centered on RGX-121 and the regulatory commentary that investors are trying to interpret.Mise à jour du récit • Feb 11
RGNX: Clinical Hold Setbacks Will Refocus Attention On Upcoming Pivotal Data
Analysts have trimmed their fair value estimate for REGENXBIO to $12.00 from $14.00, citing a reset in price targets across the Street following clinical updates. The revised estimate still reflects higher modeled revenue growth and a lower future P/E multiple in their assumptions.Article d’analyse • Feb 06
REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Jan 29
Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Dec 23
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 27% gain in the last month alone. The...Article d’analyse • Oct 09
REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29%
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 29% gain in the last month alone...Article d’analyse • Oct 03
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Aug 12
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel
NasdaqGS:RGNX 1 Year Share Price vs Fair Value Explore REGENXBIO's Fair Values from the Community and select yours With...
Mise à jour du récit • Aug 08
Gene Therapy Breakthroughs Will Unlock Expanding Future Markets
Analysts have revised REGENXBIO’s price target downward to $29.75, reflecting heightened sector scrutiny after competitor safety issues but maintaining confidence in RGX-202’s differentiated immune suppression strategy and clinical outlook. Analyst Commentary Safety issues with a competitor's product (Sarepta's Elevidys) have renewed focus on immune prophylaxis, highlighting Regenxbio's proactive approach to immune suppression with RGX-202.Article d’analyse • May 15
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for REGENXBIO Inc. ( NASDAQ:RGNX ), which a week ago released some disappointing...Article d’analyse • May 01
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders would be excited to see that the share price has had a great month, posting...Article d’analyse • Apr 24
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Nouveau récit • Mar 30
FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline
Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments.Seeking Alpha • Mar 26
5 Reasons To Buy Regenxbio Right Now
Summary Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis. Technically speaking, the stock is shifting from bearish to bullish, with significant upside potential and positive price target trends from multiple analysts. RGNX is a prime buyout candidate, with AbbVie as a likely bidder, supported by several other potential suitors in the biotech and pharma sectors that are active/interested in Gene Therapy. Read the full article on Seeking AlphaArticle d’analyse • Mar 04
The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%
To the annoyance of some shareholders, REGENXBIO Inc. ( NASDAQ:RGNX ) shares are down a considerable 27% in the last...Seeking Alpha • Jan 15
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Summary Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku. Despite historical underperformance, I remain hopeful, banking on the durability of their wet AMD treatment and will continue buying at dips, giving RGNX stock two more years. Read the full article on Seeking AlphaArticle d’analyse • Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive
Unfortunately for some shareholders, the REGENXBIO Inc. ( NASDAQ:RGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 31
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Summary Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030. RGX-202 for the treatment of patients with DMD and ABBV-RGX-314 for treatment of patients with diabetic retinopathy are other programs in pipeline; Late-stage studies starting Q4 of 2024 and 1st half 2025 respectively. Read the full article on Seeking AlphaArticle d’analyse • Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Aug 06
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Summary Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the treatment of patients with MPS II, expected in the 2nd half of 2024. Initiation of a pivotal study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q4 of 2024. Subretinal delivery of ABBV-RGX-314 for the treatment of patients with Wet-AMD is ongoing; Two studies being done are ATMOSPHERE and ASCENT and regulatory submissions U.S. And EU on track for 1st half of 2026. Read the full article on Seeking AlphaArticle d’analyse • Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that REGENXBIO Inc. ( NASDAQ:RGNX ) filed its quarterly result this time last week. The...Article d’analyse • Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
REGENXBIO Inc.'s ( NASDAQ:RGNX ) price-to-sales (or "P/S") ratio of 8.2x might make it look like a buy right now...Seeking Alpha • Jun 11
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Summary REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, and Hunter syndrome. ABBV-RGX-314, RGX-202, and RGX-121 are key pipeline candidates targeting significant markets with promising clinical data. The collaboration with AbbVie for ABBV-RGX-314 includes potential milestone payments and significant market potential in wet AMD and DR. I deem RGNX a "strong buy" due to its innovative pipeline, strategic partnerships, robust financial health, and potential market impact. Read the full article on Seeking AlphaArticle d’analyse • May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
The analysts might have been a bit too bullish on REGENXBIO Inc. ( NASDAQ:RGNX ), given that the company fell short of...Article d’analyse • Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
The REGENXBIO Inc. ( NASDAQ:RGNX ) share price has softened a substantial 26% over the previous 30 days, handing back...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$290m |
| Dec 31 2025 | US$4m | US$666k | -US$194m |
| Sep 30 2025 | n/a | n/a | -US$178m |
| Jun 30 2025 | n/a | n/a | -US$176m |
| Mar 31 2025 | n/a | n/a | -US$158m |
| Dec 31 2024 | US$5m | US$572k | -US$227m |
| Sep 30 2024 | n/a | n/a | -US$239m |
| Jun 30 2024 | n/a | n/a | -US$241m |
| Mar 31 2024 | n/a | n/a | -US$260m |
| Dec 31 2023 | US$3m | US$513k | -US$263m |
| Sep 30 2023 | n/a | n/a | -US$261m |
| Jun 30 2023 | n/a | n/a | -US$274m |
| Mar 31 2023 | n/a | n/a | -US$270m |
| Dec 31 2022 | US$2m | US$475k | -US$280m |
| Sep 30 2022 | n/a | n/a | US$74m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$101m |
| Dec 31 2021 | US$3m | US$448k | US$128m |
| Sep 30 2021 | n/a | n/a | -US$212m |
| Jun 30 2021 | n/a | n/a | -US$145m |
| Mar 31 2021 | n/a | n/a | -US$121m |
| Dec 31 2020 | US$2m | US$428k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$91m |
| Jun 30 2020 | n/a | n/a | -US$135m |
| Mar 31 2020 | n/a | n/a | -US$103m |
| Dec 31 2019 | US$2m | US$382k | -US$95m |
Rémunération vs marché: La rémunération totale de Curran ($USD 4.20M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.67M ).
Rémunération et revenus: La rémunération de Curran a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Curran Simpson (63 yo)
1.8yrs
Titularisation
US$4,200,712
Compensation
Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 1.8yrs | US$4.20m | 0.089% $ 273.5k | |
| Executive VP & Chief Strategy and Legal Officer | 9.8yrs | US$2.04m | 0.17% $ 528.4k | |
| Executive VP & Chief Medical Officer | 7.1yrs | US$1.80m | 0.17% $ 511.7k | |
| Executive VP & CFO | 1.7yrs | US$3.21m | 0.019% $ 58.6k | |
| Executive VP of Product Development & CTO | 1.2yrs | pas de données | 0.16% $ 490.7k | |
| Executive VP & Chief Scientific Officer | 9.2yrs | US$2.96m | 0.11% $ 348.4k | |
| Chief Communications & People Officer | 8.6yrs | pas de données | pas de données | |
| Executive VP & Chief Commercial Officer | 7.8yrs | pas de données | pas de données | |
| SVP of Global Regulatory Strategy and Quality | less than a year | pas de données | pas de données | |
| Clinical Development Lead | no data | pas de données | pas de données |
7.1yrs
Durée moyenne de l'emploi
54yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de RGNX est chevronnée et expérimentée (7.1 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 1.8yrs | US$4.20m | 0.089% $ 273.5k | |
| Independent Director | 10.6yrs | US$339.99k | 0.022% $ 67.4k | |
| Independent Director | 4.7yrs | US$339.99k | 0.022% $ 67.4k | |
| Independent Director | 11yrs | US$327.49k | 0.022% $ 67.4k | |
| Member of Scientific Advisor | no data | pas de données | pas de données | |
| Independent Director | 17.3yrs | US$319.99k | 6.14% $ 18.9m | |
| Member of Scientific Advisor | no data | pas de données | pas de données | |
| Independent Director | 8yrs | US$327.49k | 0.022% $ 67.4k | |
| Lead Independent Director | 9.8yrs | US$359.99k | 0.022% $ 67.4k | |
| Independent Director | 4.7yrs | US$324.99k | 0.022% $ 67.4k | |
| Chairman | 17.2yrs | US$354.99k | 0.84% $ 2.6m | |
| Independent Director | 3.9yrs | US$329.99k | 0.028% $ 85.3k |
8.9yrs
Durée moyenne de l'emploi
70.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de RGNX sont considérés comme expérimentés (ancienneté moyenne 8.9 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 13:34 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
REGENXBIO Inc. est couverte par 24 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |